Arthrosi Therapeutics, Inc. today announced a joint venture in Guangzhou China with Ruiao Biopharmaceutical Technology Co., Ltd. (“a subsidiary of  ApicHope  Phamaceutical”) to form Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd.

Jade Mountain Acquisition, a blank check company targeting the healthcare and technology sectors, filed on Thursday with the SEC to raise up to $100 million.

N/A

 Acepodia announced that an article describing the efficacy profile of ACE1702, Acepodia’s novel, off-the-shelf natural killer (NK) cell therapy against HER2-expressing solid tumors, was published in the journal Cancers.

With AR882 showing strong efficacy and safety profile in Phase 2a study, Arthrosi is accelerating the development and looking to complete the Phase 2 studies by the middle of 2022.

Advaxis, Inc. announced updated data from the Company’s ongoing Phase 1/2 study evaluating ADXS-503 in combination with KEYTRUDA^® which will be presented as a poster at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.

N/A

When Acepodia CEO Sonny Hsiao began developing a list of candidates to fill the chief financial officer role at the biotechnology company that he had cofounded, it may have surprised some to see Jimmy Lai make the list.

Acepodia, a biotechnology company developing next generation solid tumor and hematologic cancer cell therapies, today presented new preclinical data showing that the company’s CD20-targeting, natural killer (NK)-like gamma-delta T cell therapy, ACE1831, which is being developed for hematological cancers, demonstrated prolonged survival in vivo.

 Acepodia, a biotechnology company developing next generation solid tumor and hematologic cancer cell therapies, today announced the appointments of Thorsten Graef, M.D., Ph.D., as chief medical officer and Michael Brock as chief strategy officer.